DKB-123

DKB-123 is an investigational drug candidate being developed by Dongkook Pharma, a South Korean pharmaceutical company, for the treatment of wounds and the promotion of tissue repair. Currently in the early stages of development, DKB-123 is part of Dongkook's R&D pipeline focusing on regenerative medicine and wound care management. While specific details regarding its molecular structure, biological target, and mechanism of action have not been extensively disclosed in public domain literature, it is classified as a new drug candidate intended to enhance natural healing processes. The project leverages Dongkook Pharma's historical expertise in the wound care sector, aiming to provide improved therapeutic options for tissue recovery and skin regeneration.